Table 1.
Characteristics of patients in the TOUR study (n = 103)
| Age (yr, mean, range) | 38.0 | 18–81 |
| Sex (m: n; %) | 58 | 56.3% |
| Duration of disease (yr; mean, range) | 8.6 | 0–50 |
| BMI (kg/m2); (mean, range) | 25.5 | 14.8–43.9 |
| Race (n, %) | ||
| White | 87 | 84.5% |
| Black/African American | 6 | 5.8% |
| Asian | 2 | 1.9% |
| Other | 5 | 4.9% |
| Unknown | 3 | 2.9% |
| Current smoker | 2 | 1.9% |
| Site of disease (Montreal classification) | ||
| E1 | 7 | 7% |
| E2 | 45 | 44% |
| E3 | 51 | 50% |
| Prior medication use (n, %) | ||
| Mesalamine | 97 | 92.2% |
| Steroids (at baseline; wk 0) | 66 | 64.1% |
| Azathioprine/6-MP | 46 | 44.7% |
| Methotrexate (oral or sc) | 22 | 21.4 |
| Vedolizumab | 63 | 61.2% |
| Ustekinumab | 8 | 7.8% |
| Anti-TNF | 91 | 94.8% |
| Total no. of prior biologics | ||
| 0 | 3 | 2.9% |
| 1 | 31 | 30.1% |
| 2 | 38 | 36.9% |
| 3 | 24 | 23.3% |
| 4 | 7 | 6.8% |
| SCCAI >2 | 87 | 84.5% |
| SCCAI ≤2 | 16 | 15.5% |
| Mayo endoscopy scorea | ||
| 0 | 4 | 3.9% |
| 1 | 7 | 6.8% |
| 2 | 37 | 35.9% |
| 3 | 52 | 50.5% |
| Unknown | 3 | 2.9% |
BMI, body mass index; SCCAI, Simple Clinical Colitis Activity Index; TNF, tumor necrosis factor; TOUR, tofacitinib response in ulcerative colitis; UC, ulcerative colitis.
a
Endoscopy score before tofacitinib initiation (most recent colonoscopy or sigmoidoscopy reported in the system).